Is There a Wegovy Equivalent to Mounjaro 7.5mg?

The misconception: that dose numbers on two different medicines are directly interchangeable

A question our prescribers hear most weeks is whether moving from Mounjaro 7.5mg to Wegovy means taking a dose that carries the same number. It does not. The milligram figures refer to different molecules at different concentrations, and comparing them numerically is a bit like comparing the horsepower ratings of a petrol and an electric car — the units look the same but describe different things.

Mounjaro (tirzepatide) activates two gut-hormone receptors simultaneously: GIP and GLP-1. Wegovy (semaglutide) targets GLP-1 only. That structural difference means the medicines produce different appetite-reduction effects at doses whose numbers happen to be similar. The NHS medicines page for tirzepatide and the corresponding page for semaglutide explain the mechanisms clearly, and neither suggests the dose ladders are equivalent.

What clinicians do instead of a numerical conversion is ask: at this point in your treatment, which medicine is licensed for you, what does your response look like, and what does the evidence say about likely outcomes? If you want to understand the fuller picture of how the two schedules sit alongside each other, our guide to equivalent doses across the full ladders covers each step in detail.

Where Mounjaro 7.5mg sits in its schedule, and the Wegovy doses usually placed alongside it

Mounjaro's licensed dose ladder in the UK runs 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg, each pen covering four weekly injections, titrated roughly every four weeks by your prescriber. The 7.5mg pen is the third rung — patients reach it after spending at least four weeks each at 2.5mg and 5mg, assuming their prescriber is satisfied with tolerability and response.

Wegovy's standard maintenance path runs 0.25mg, 0.5mg, 1.0mg, 1.7mg, and 2.4mg. If you are thinking about what the Wegovy equivalent to 7.5mg Mounjaro might be in practical terms, most clinical discussions place Mounjaro 7.5mg loosely alongside Wegovy 1.7mg or 2.4mg, the stage where patients on either medicine are typically moving toward or reaching a meaningful therapeutic dose. A more detailed breakdown by starting dose is available on our page covering how to think about a Mounjaro-to-Wegovy dose conversion.

The table below sets out factual, cited comparisons at the points most relevant to this question.

Sources: SURMOUNT-1, NEJM; STEP 1, NEJM; NICE TA1026.

What the evidence actually shows at these stages of treatment

Comparing the two medicines at the mid-ladder stage is genuinely difficult, because the trials measured outcomes at their respective highest doses over defined periods, not at each intermediate step. SURMOUNT-1 reported roughly 20–21% average body-weight reduction at Mounjaro 15mg over 72 weeks. STEP 1 reported roughly 15% at Wegovy 2.4mg over 68 weeks. Neither trial isolated the 7.5mg or 1.7mg steps as the end-point, so mid-schedule figures should be interpreted with that caveat.

The head-to-head SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, compared tirzepatide directly with semaglutide 2.4mg over 72 weeks in adults with obesity. Tirzepatide produced greater average weight reduction. Wegovy's newer 7.2mg dose is narrowing that gap in separate analyses, though it was not part of SURMOUNT-5. For a side-by-side of the two medicines across all the headline evidence, our Wegovy vs Mounjaro comparison covers the full picture.

What this means practically: patients at Mounjaro 7.5mg are not at a plateau equivalent to Wegovy's highest dose. There is headroom to 15mg if the prescriber decides it is appropriate. Patients at Wegovy 2.4mg are at the standard maintenance ceiling, though the 7.2mg option now exists for eligible people. Neither path is inherently superior for every person, individual response, tolerability, and medical history all shape the outcome.

Switching between the two medicines, and what to do next

Some people reach Mounjaro 7.5mg and wonder whether switching to Wegovy would suit them better, or vice versa. Others are transferred from a previous provider and want to understand where they sit on a new schedule. The honest answer is that switching is a clinical decision, not a numerical one. A prescriber reviews your current dose, your response, your tolerability history, and any relevant medical background before recommending a starting point on the new medicine, including what a Wegovy 1mg dose corresponds to on the Mounjaro schedule.

At nume, every repeat and every transfer is reviewed by a real prescriber before anything is dispatched. Our clinical team is GPhC-registered, and the same-day review applies to transfer patients too. If you are currently at Mounjaro 5mg and considering what comes next, our page on that step may be useful reading before your consultation. For a wider overview of all available weight-loss treatments, the treatment overview sets out what is licensed in the UK.

Which medicine suits you, and at which dose, is a clinical decision our prescribers make with you. Speak to our prescribers through a free consultation, reviewed the same day.